Stage IIIB Prostate Cancer AJCC v8 Completed Phase 1 Trials for JNJ-40346527 (DB12504)

IndicationStatusPhase
DBCOND0109671 (Stage IIIB Prostate Cancer AJCC v8)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03177460Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate CancerTreatment